ADiTx Therapeutics, Inc. (NASDAQ:ADTX) Short Interest Up 354.0% in December

ADiTx Therapeutics, Inc. (NASDAQ:ADTX) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 2,070,000 shares, an increase of 354.0% from the December 15th total of 455,900 shares. Based on an average trading volume of 3,080,000 shares, the short-interest ratio is currently 0.7 days.

Shares of ADiTx Therapeutics stock opened at $0.46 on Friday. ADiTx Therapeutics has a 52-week low of $0.43 and a 52-week high of $6.73. The company has a 50-day simple moving average of $0.87 and a two-hundred day simple moving average of $1.65.

Separately, Zacks Investment Research cut shares of ADiTx Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 10th.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its holdings in shares of ADiTx Therapeutics by 12.5% during the second quarter. Geode Capital Management LLC now owns 92,015 shares of the company’s stock valued at $238,000 after purchasing an additional 10,229 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of ADiTx Therapeutics by 16.6% during the second quarter. Vanguard Group Inc. now owns 197,093 shares of the company’s stock valued at $510,000 after purchasing an additional 28,058 shares during the last quarter. State Street Corp purchased a new position in shares of ADiTx Therapeutics during the second quarter valued at approximately $37,000. CVI Holdings LLC purchased a new position in shares of ADiTx Therapeutics during the third quarter valued at approximately $995,000. Finally, Inspire Advisors LLC purchased a new position in shares of ADiTx Therapeutics during the third quarter valued at approximately $25,000. 9.97% of the stock is owned by hedge funds and other institutional investors.

About ADiTx Therapeutics

ADiTx Therapeutics, Inc, a biotech company, develops technologies focuses on improving the health of the immune system through immune reprogramming and monitoring. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues.

Read More: Special Dividends

Receive News & Ratings for ADiTx Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADiTx Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.